← Leaderboards
Weidong Wang
University Of Oklahoma Hlth Sciences Ctr
$5,503,980
Attributed
$5,973,331
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $983.7K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,973,331 · 4
By mechanism
R01$5,529,331 · 3
R56$444,000 · 1
Top collaborators
- Li Qiang2 shared
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Sarah X Zhang$9,089,188
- Jialing Lin$4,348,011
- Jeanie Beatrice Tryggestad$2,778,936
- Faizah Naheed Bhatti$1,154,081
- Altaf Mohammed$74,000
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDiabetes MellitusInsulinCellsPlayInsulin SensitivityAnalogSmall MoleculeCellular AssayWeight GainIn VivoLeadObesityAnimalsCytoprotectionHalf-LifeClinical DevelopmentDiabetic MouseHigh Throughput ScreeningBinding ProteinsDrug KineticsEndoplasmic Reticulum StressCessation Of LifeDiabetic
Grant awards (16)
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment$554,970
R01 · FY2025 · DK · contact PI
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment$392,841
R01 · FY2025 · DK · contact PI
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment$439,260
R01 · FY2024 · DK · contact PI
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment$368,836
R01 · FY2024 · DK · contact PI
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment$460,068
R01 · FY2023 · DK · contact PI
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment$384,202
R01 · FY2023 · DK · contact PI
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment$462,522
R01 · FY2022 · DK · contact PI
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment$395,452
R01 · FY2022 · DK · contact PI
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment$476,180
R01 · FY2021 · DK · contact PI
Cytoprotection and the mechanism of action of a natural product Khellin against ER stress$362,500
R01 · FY2021 · DK · contact PI
Cytoprotection and the mechanism of action of a natural product Khellin against ER stress$145,000
R01 · FY2021 · DK · contact PI
Cytoprotection and the mechanism of action of a natural product Khellin against ER stress$362,500
R01 · FY2020 · DK · contact PI
Cytoprotection and the mechanism of action of a natural product Khellin against ER stress$362,500
R01 · FY2019 · DK · contact PI
Cytoprotection and the mechanism of action of a natural product Khellin against ER stress$362,500
R01 · FY2018 · DK · contact PI
Preclinical Development of Khellin Analogs for Anti-Diabetic Therapy$222,000
R56 · FY2017 · DK · contact PI
Preclinical Development of Khellin Analogs for Anti-Diabetic Therapy$222,000
R56 · FY2016 · DK · contact PI